Assessment of Antibody Assays for Identifying and Distinguishing Recent from Long-Term HIV Type 1 Infection
- 20 January 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 17 (2) , 137-146
- https://doi.org/10.1089/08892220150217229
Abstract
We evaluated 16 antibody assays for their performance in discriminating recent from established HIV-1 infection. These approaches were based on antigen specificity, quantity, conformation dependence, and avidity/affinity of HIV-specific antibodies. A panel of 41 sera from subjects who had seroconverted in the previous 2-6 months (n = 20) and from subjects with established infection (>1 year, n = 21) were run in each assay. Compared with anti-Gag and anti-Pol responses, quantitative anti-Env antibody levels were initially lower and ultimately higher, resulting in the greatest spread and least overlap between incident and established infection. Quantitative measurement included end-point titer in Western blot, end-point titer or response at a given dilution in solid-phase enzyme immunoassays (EIAs) with recombinant proteins or synthetic peptides, and IgG capture assays that reflect the relative proportion of IgG that is anti-HIV antibody. Focusing on the anti-env response, we measured specific responses to the V3 region of gp120, to the CD4-binding site of gp120, to a peptide corresponding to the immunodominant region of gp41, and to conformation-dependent epitopes of gp120. We also measured antibody affinity for gp41 peptide and the relative avidity for gp120 or gp41 peptide by thermal or urea-elution assays. These assays also discriminated recent from established infection but were not necessarily superior to the quantitative anti-Env assays. Appropriate approaches, based on distinct principles or combination of principles, can be used to develop simple assays for identifying individuals recently infected with HIV-1.Keywords
This publication has 38 references indexed in Scilit:
- Short Communication: A Novel Mutation (F227L) Arises in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 on Dose-Escalating Treatment of HIV Type 1-Infected Cell Cultures with the Nonnucleoside Reverse Transcriptase Inhibitor Thiocarboxanilide UC-781AIDS Research and Human Retroviruses, 1998
- An Investigation of the High-Avidity Antibody Response to Glycoprotein 120 of Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1997
- Human Immunodeficiency Virus Type I-Infected Patients with No Disease Progression Display Highavidity Antibody Production to Autologous V3 SequencesThe Journal of Infectious Diseases, 1995
- Comparison of the immune response to recombinant gp120 in humans and chimpanzeesAIDS, 1994
- Affinity of anti‐GP41 antibody in patients infected with human immunodeficiency virus type IEuropean Journal of Clinical Investigation, 1993
- The Reactivities of HIV-1+Human Sera with Solid-Phase V3 Loop Peptides Can Be Poor Predictors of Their Reactivities with V3 Loops on Native gp120 MoleculesAIDS Research and Human Retroviruses, 1993
- Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assayAIDS, 1990
- Prospects for prevention of and early intervention against HIVPublished by American Medical Association (AMA) ,1989
- Denaturation of globular proteins by urea: breakdown of hydrogen or hydrophobic bonds?Trends in Biochemical Sciences, 1988
- Variation in human T lymphotropic virus III (HTLV-III) antibodies in homosexual men: decline before onset of illness related to acquired immune deficiency syndrome (AIDS).BMJ, 1985